The History of Antidiabetic Drug Metformin

Metformin is a widely used antidiabetic drug that has been on the market for over six decades. It was first approved for use in France in 1957 and later introduced in the United States in 1995. Today, it is one of the most commonly prescribed medications for the treatment of type 2 diabetes, and its use has expanded beyond diabetes to include other conditions such as polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD).

The history of metformin can be traced back to the Middle Ages when traditional healers used extracts of a plant called Galega officinalis, also known as French lilac or goat’s rue, to treat diabetes. In the 1920s, researchers discovered that a compound called guanidine, which is present in Galega, had antidiabetic effects. However, guanidine was found to have serious side effects and was not suitable for use as a medicine.

In the 1940s, researchers at the French pharmaceutical company Rhône-Poulenc, now Sanofi, started investigating guanidine derivatives as potential antidiabetic drugs. In 1957, the company introduced a compound called metformin, which was found to have antidiabetic effects without the serious side effects of guanidine. Metformin was initially marketed under the trade name Glucophage and was approved for use in France.

Metformin works by reducing the production of glucose by the liver and increasing insulin sensitivity in peripheral tissues, particularly muscle and fat. This leads to a decrease in blood glucose levels and an improvement in insulin sensitivity. In addition to its antidiabetic effects, metformin has been shown to have other beneficial effects, such as reducing cardiovascular risk and improving lipid profiles.

In the decades that followed its introduction, metformin was widely prescribed for the treatment of type 2 diabetes. However, its use was limited in the United States due to concerns about its safety and efficacy. In 1994, the Food and Drug Administration (FDA) finally approved metformin for use in the United States, and its use quickly became widespread. Today, metformin is one of the most commonly prescribed antidiabetic drugs and is considered a first-line treatment for type 2 diabetes.

In recent years, the use of metformin has expanded beyond diabetes to include other conditions such as PCOS and NAFLD. PCOS is a condition that affects women of reproductive age and is characterized by irregular periods, high levels of androgens (male hormones), and polycystic ovaries. Metformin has been shown to improve insulin sensitivity and reduce androgen levels in women with PCOS, leading to improved symptoms and reduced risk of developing type 2 diabetes. NAFLD is a condition in which excess fat accumulates in the liver, leading to inflammation and liver damage. Metformin has been shown to improve insulin sensitivity and reduce liver fat in individuals with NAFLD, reducing the risk of liver damage and progression to liver cirrhosis.

Metformin is a widely used antidiabetic drug with a history that dates back to the Middle Ages. Originally developed as a treatment for type 2 diabetes, its use has expanded to include other conditions such as PCOS and NAFLD. Its long history of use and proven efficacy and safety make it an important part of modern medicine.

References:

1. Bailey CJ, Day C. Metformin. N Engl J Med. 1996;334(9):574-579.

2. Einhorn D, Rendell M, Rosenzweig J, et al. Metformin: an update. Ann Intern Med. 2002;137(6):531

*This article was produced with the assistance of artificial intelligence. Please always check and confirm with your own sources, and always consult with your healthcare professional when seeking medical treatment.